Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity

Journal of Nuclear Medicine Technology

Volumn 41, Issue 3, 2013, Pages 170-181

  de Geus Oei, Lioe Fee ^a   Mavinkurve Groothuis, Annelies M C ^a   Bellersen, Louise ^a   Gotthardt, Martin ^a   Oyen, Wim J G ^a   Kapusta, Livia ^a,b   van Laarhoven, Hanneke W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Cancer treatment; Cardiotoxicity; Early detection

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ALEMTUZUMAB; ALPHA INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FATTY ACID; FLUOROURACIL; HOMOHARRINGTONINE; IFOSFAMIDE; INTERLEUKIN 2; IODOFILTIC ACID I 123; MITOXANTRONE; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; RETINOIC ACID; RITUXIMAB; TECHNETIUM 99M; THALIDOMIDE; TRASTUZUMAB; TRASTUZUMAB IN 111; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; BRADYCARDIA; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CELL DEATH; DISEASE COURSE; DRUG MEGADOSE; EARLY DIAGNOSIS; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HEMORRHAGIC MYOCARDITIS; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; ISOTOPE LABELING; MYOCARDITIS; NON INVASIVE PROCEDURE; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; QT PROLONGATION; SCINTIANGIOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TORSADE DES POINTES;

CANCER TREATMENT; CARDIOTOXICITY; EARLY DETECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; EARLY DIAGNOSIS; HEART; HUMANS; NEOPLASMS; RADIONUCLIDE IMAGING; SYMPATHETIC NERVOUS SYSTEM;

EID: 84884992742     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.082784     Document Type: Article

References (113)

1. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 2009;4: 77-88.
2. Procter M, Suter TM, de Azambuja E, et al. Longer-term assessment of trastuzumab- related cardiac adverse events in the herceptin adjuvant (HERA) trial. J Clin Oncol. 2010;28:3422-3428.
3. Panjrath GS, Jain D. Trastuzumab-induced cardiac dysfunction. Nucl Med Commun. 2007;28:69-73.
4. Trudeau M, Charbonneau F, Gelmon K, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol. 2005;6: 886-898.
5. Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol. 2001;12:1067-1073.
6. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302-2313.
7. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:72-85.
8. Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811-7819.
9. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol. 2010;28:3416-3421.
10. Panjrath GS, Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. J Nucl Cardiol. 2006;13:415-426.
11. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
12. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010;170:1247-1255.
13. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561-578.
14. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109: 3122-3131.
15. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
16. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
17. Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61(suppl 2):58-66.
18. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010;106:35-46.
19. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-465.
20. Grazette LP, Boecker W, Matsui T, et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol. 2004;44:2231-2238.
21. Gassmann M, Casagranda F, Orioli D, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378: 390-394.
22. Perik PJ, de Korte MA, van Veldhuisen DJ, Gietema JA, Sleijfer DT, de Vries EG. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients. Expert Rev Anticancer Ther. 2007;7:1763-1771.
23. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005;23:2900-2902.
24. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
25. Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart: myocyte loss and reactive cellular hypertrophy. Circ Res. 1991;68:1560-1568.
26. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008:CD003917.
27. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709.
28. Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:2196-2201.
29. Morris PG, Hudis CA. Trastuzumab-related cardiotoxicity following anthracycline- based adjuvant chemotherapy: how worried should we be? J Clin Oncol. 2010;28:3407-3410.
30. Slamon DJ, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study. Slides and abstract presented at: San Antonio Breast Cancer Conference; December 9-13, 2009; San Antonio, TX. Available at: http://www.abstracts2view.com/sabcs09/view. php?nu5SABCS09L_1752. Accessed January 12, 2011.
31. Altena R, Boekhout AH. A randomized, pharmacologic intervention study evaluating the effect of the angiotensin II-receptor blocker candesartan versus placebo to prevent trastuzumab-associated cardiotoxicity in women with early breast cancer [abstract]. J Clin Oncol. 2010;28(15 suppl):TPS108.
32. Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85:894-896.
33. Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev. 1999;25:237-247.
34. Kapusta L, Groot-Loonen J, Thijssen JM, De Graaf R, Daniels O. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy. Med Pediatr Oncol. 2003;41:426-435.
35. Marwick TH. Measurement of strain and strain rate by echocardiography: ready for prime time? J Am Coll Cardiol. 2006;47:1313-1327.
36. Mavinkurve-Groothuis AM, Weijers G, Groot-Loonen J, et al. Interobserver, intraobserver and intrapatient reliability scores of myocardial strain imaging with 2-d echocardiography in patients treated with anthracyclines. Ultrasound Med Biol. 2009;35:697-704.
37. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1349-1353.
38. Horacek JM, Pudil R, Tichy M, et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005; 52:430-434.
39. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49:330-352.
40. Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus HA. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol. 2006;48:2192-2194.
41. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405-1410.
42. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749-2754.
43. Mantovani G, Madeddu C, Cadeddu C, et al. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist. 2008;13:1296-1305.
44. Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol. 2004;94: 249-251.
45. Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol. 2009;10:391-399.
46. Bellenger NG, Burgess MI, Ray SG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J. 2000;21:1387-1396.
47. Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461-470.
48. Walker J, Bhullar N, Fallah-Rad N, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol. 2010;28:3429-3436.
49. Corapcioglu F, Sarper N, Berk F, Sahin T, Zengin E, Demir H. Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography. Pediatr Hematol Oncol. 2006;23:71-80.
50. Takuma S, Ota T, Muro T, et al. Assessment of left ventricular function by realtime 3-dimensional echocardiography compared with conventional noninvasive methods. J Am Soc Echocardiogr. 2001;14:275-284.
51. Phan TT, Abozguia K, Shivu GN, et al. Increased atrial contribution to left ventricular filling compensates for impaired early filling during exercise in heart failure with preserved ejection fraction. J Card Fail. 2009;15:890-897.
52. Gosselink AT, Liem AL, Reiffers S, Zijlstra F. Prognostic value of predischarge radionuclide ventriculography at rest and exercise after acute myocardial infarction treated with thrombolytic therapy or primary coronary angioplasty. The Zwolle Myocardial Infarction Study Group. Clin Cardiol. 1998;21: 254-260.
53. Yu CM, Bax JJ, Gorcsan J III. Critical appraisal of methods to assess mechanical dyssynchrony. Curr Opin Cardiol. 2009;24:18-28.
54. Yamamoto A, Takahashi N, Munakata K, et al. Global and regional evaluation of systolic and diastolic left ventricular temporal parameters using a novel program for ECG-gated myocardial perfusion SPECT: validation by comparison with gated equilibrium radionuclide angiography and speckle-tracking radial strain from echocardiography. Ann Nucl Med. 2007;21:115-121.
55. Mavinkurve-Groothuis AMC, Groot-Loonen J, Marcus KA, et al. Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. Ultrasound Med Biol. 2010;36:1783- 1791.
56. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics. 1992;89:942-949.
57. Hesse B, Lindhardt TB, Acampa W, et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging. 2008;35:851- 885.
58. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: seven-year experience using serial radionuclide angiocardiography. Am J Med. 1987;82:1109-1118.
59. Nousiainen T, Vanninen E, Jantunen E, et al. Comparison of echocardiography and radionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. J Intern Med. 2001;249:297-303.
60. Mitani I, Jain D, Joska TM, Burtness B, Zaret BL. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol. 2003;10:132-139.
61. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266:1672- 1677.
62. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324:808-815.
63. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
64. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007;25:3525-3533.
65. Calnon DA, Kastner RJ, Smith WH, Segalla D, Beller GA, Watson DD. Validation of a new counts-based gated single photon emission computed tomography method for quantifying left ventricular systolic function: comparison with equilibrium radionuclide angiography. J Nucl Cardiol. 1997;4:464-471.
66. Groch MW, Marshall RC, Erwin WD, Schippers DJ, Barnett CA, Leidholdt EM Jr. Quantitative gated blood pool SPECT for the assessment of coronary artery disease at rest. J Nucl Cardiol. 1998;5:567-573.
67. Groch MW, DePuey EG, Belzberg AC, et al. Planar imaging versus gated blood-pool SPECT for the assessment of ventricular performance: a multicenter study. J Nucl Med. 2001;42:1773-1779.
68. Hacker M, Hoyer X, Kupzyk S, et al. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006;22:407-416.
69. Massardo T, Jaimovich R, Lavados H, et al. Comparison of radionuclide ventriculography using SPECT and planar techniques in different cardiac conditions. Eur J Nucl Med Mol Imaging. 2007;34:1735-1746.
70. Odagiri K, Wakabayashi Y, Tawarahara K, et al. Evaluation of right and left ventricular function by quantitative blood-pool SPECT (QBS): comparison with conventional methods and quantitative gated SPECT (QGS). Ann Nucl Med. 2006;20:519-526.
71. Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium- 111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med. 1995;36:2044-2049.
72. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med. 1979;300:278-283.
73. Dardir MD, Ferrans VJ, Mikhael YS, et al. Cardiac morphologic and functional changes induced by epirubicin chemotherapy. J Clin Oncol. 1989;7:947-958.
74. Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol. 1984;2:112-117.
75. Druck MN, Gulenchyn KY, Evans WK, et al. Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer. 1984;53:1667-1674.
76. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure- function relationships in doxorubicin cardiomyopathy. Am Heart J. 1981;102:709-718.
77. Strashun A. Adriamycin, congestive cardiomyopathy, and metaiodobenzylguanidine. J Nucl Med. 1992;33:215-222.
78. Lautamaki R, Tipre D, Bengel FM. Cardiac sympathetic neuronal imaging using PET. Eur J Nucl Med Mol Imaging. 2007;34(suppl 1):S74-S85.
79. Francis GS, Cohn JN. The autonomic nervous system in congestive heart failure. Annu Rev Med. 1986;37:235-247.
80. Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer. 1995;31A:26-31.
81. Dae MW, O'Connell JW, Botvinick EH, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation. 1989;79:634-644.
82. Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin- induced cardiac neurotoxicity: study with iodine 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol. 1996;3:37-41.
83. Arimoto T, Takeishi Y, Niizeki T, et al. Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure. Ann Nucl Med. 2005;19:535-540.
84. Matsuo S, Nakamura Y, Tsutamoto T, Kinoshita M. Impairments of myocardial sympathetic activity may reflect the progression of myocardial damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol. 2002;9:407-412.
85. Ohshima S, Isobe S, Izawa H, et al. Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol. 2005;46:2061-2068.
86. Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments: comparison with neurohumoral factors. Circ J. 2002;66:537-543.
87. Fujimoto S, Inoue A, Hisatake S, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging. 2004;31:1356-1361.
88. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
89. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579-590.
90. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging. 2007;34(suppl 1):S62-S73.
91. Wakasugi S, Fischman AJ, Babich JW, et al. Metaiodobenzylguanidine: evaluation of its potential as a tracer for monitoring doxorubicin cardiomyopathy. J Nucl Med. 1993;34:1283-1286.
92. Jeon TJ, Lee JD, Ha JW, Yang WI, Cho SH. Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine- 131 MIBG autoradiography and PGP 9.5 immunohistochemistry. Eur J Nucl Med. 2000;27:686-693.
93. Meredith IT, Eisenhofer G, Lambert GW, Dewar EM, Jennings GL, Esler MD. Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation. 1993;88:136-145.
94. Estorch M, Carrio I, Berna L, Lopez-Pousa J, Torres G. Myocardial iodinelabeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol. 1995;2:126-132.
95. Takano H, Ozawa H, Kobayashi I, et al. Myocardial sympathetic dysinnervation in doxorubicin cardiomyopathy. J Cardiol. 1996;27:49-55.
96. Pierpont GL, DeMaster EG, Reynolds S, Pederson J, Cohn JN. Ventricular myocardial catecholamines in primates. J Lab Clin Med. 1985;106:205-210.
97. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal function using PET imaging. J Nucl Cardiol. 2004;11:603-616.
98. Carrio I, Estorch M, Berna L, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium 111 myosin-specific monoclonal antibody studies. Eur J Nucl Med. 1991;18:806-812.
99. Estorch M, Carrio I, Berna L, et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J Nucl Med. 1990;31:1965-1969.
100. Carrio I, Lopez-Pousa A, Estorch M, et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J Nucl Med. 1993;34:1503-1507.
101. Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998;16:86-92.
102. Maini CL, Sciuto R, Ferraironi A, et al. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. J Nucl Cardiol. 1997;4:502-508.
103. Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, et al. Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction. Ann Oncol. 1994;5: 617-622.
104. Jain D, Zaret BL. Antimyosin cardiac imaging: will it play a role in the detection of doxorubicin cardiotoxicity? J Nucl Med. 1990;31:1970-1974.
105. Narula J, Strauss HW, Khaw BA. Antimyosin positivity in doxorubicin cardiotoxicity: earlier than the conventional evidence. J NuclMed. 1993;34:1507-1509.
106. Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake. Clin Physiol. 2001;21:123-128.
107. Bennink RJ, van den Hoff MJ, van Hemert FJ, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med. 2004;45:842-848.
108. Panjrath GS, Patel V, Valdiviezo CI, Narula N, Narula J, Jain D. Potentiation of doxorubicin cardiotoxicity by iron loading in a rodent model. J Am Coll Cardiol. 2007;49:2457-2464.
109. Saito K, Takeda K, Imanaka-Yoshida K, Imai H, Sekine T, Kamikura Y. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings. Ann Nucl Med. 2003;17: 481-488.
110. Saito K, Takeda K, Okamoto S, et al. Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method. J Nucl Cardiol. 2000;7:553-561.
111. Behr TM, Behe M, Wormann B. Trastuzumab and breast cancer. N Engl J Med. 2001;345:995-996.
112. Perik PJ, Lub-de Hooge MN, Gietema JA, et al. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2006;24:2276- 2282.
113. de Korte MA, de Vries EG, Lub-de Hooge MN, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer. 2007;43:2046-2051.